|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology显示文摘 | Bernard Levin David A. Lieberman Beth McFarland Kimberly S. Andrews Durado Brooks John Bond Chiranjeev Dash Francis M. Giardiello Seth Glick David Johnson C. Daniel Johnson Theodore R. Levin Perry J. Pickhardt Douglas K. Rex Robert A. Smith Alan Thorson S | 2008 | Gastroenterology2008，，5： | 8 |
| 2 | Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease显示文摘 | Andrew D. Yeoman Rachel H. Westbrook Thawab Al‐Chalabi Ivana Carey Nigel D. Heaton Bernard C. Portmann Michael A. Heneghan | 2009 | Hepatology2009，，： | 3 |
| 3 | Interactive labelling of a multivariate dataset for supervised machine learning using linked visualisations,clustering,and active learning显示文摘Supervised machine learning techniques require labelled multivariate training datasets.Many approaches address the issue of unlabelled datasets by tightly coupling machine learning algorithms with interactive visualisations.Using appropriate techniques,analysts can play an active role in a highly interactive and iterative machine learning process to label the dataset and create meaningful partitions.While this principle has been implemented either for unsupervised,semi-supervised,or supervised machine learning tasks,the combination of all three methodologies remains challenging.In this paper,a visual analytics approach is presented,combining a variety of machine learning capabilities with four linked visualisation views,all integrated within the mVis(multivariate Visualiser)system.The available palette of techniques allows an analyst to perform exploratory data analysis on a multivariate dataset and divide it into meaningful labelled partitions,from which a classifier can be built.In the workflow,the analyst can label interesting patterns or outliers in a semi-supervised process supported by active learning.Once a dataset has been interactively labelled,the analyst can continue the workflow with supervised machine learning to assess to what degree the subsequent classifier has effectively learned the concepts expressed in the labelled training dataset.Using a novel technique called automatic dimension selection,interactions the analyst had with dimensions of the multivariate dataset are used to steer the machine learning algorithms.A real-world football dataset is used to show the utility of mVis for a series of analysis and labelling tasks,from initial labelling through iterations of data exploration,clustering,classification,and active learning to refine the named partitions,to finally producing a high-quality labelled training dataset suitable for training a classifier.The tool empowers the analyst with interactive visualisations including scatterplots,parallel coordinates,similarity maps for records,and a new similarity map for partitions. | Mohammad Chegini Jürgen Bernard Philip Berger Alexei Sourin Keith Andrews Tobias Schreck | 2019 | Visual Informatics2019，3，1： | 3 |
| 4 | Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves:A single-center experience显示文摘AIM To investigate the clinical outcomes of transcatheter aortic valve implantation(TAVI) with the SAPIEN 3 transcatheter heart valve(S3-THV) vs the SAPIEN XT valve(XT-THV).METHODS We retrospectively analyzed 507 patients that underwent TAVI with the XT-THV and 283 patients that received the S3-THV at our institution between March 2010 and December 2015.RESULTS Thirty-day mortality(3.5% vs 8.7%:OR=0.44,P=0.21) and 1-year mortality(25.7% vs 20.1%,P=0.55) were similar in the S3-THV and the XT-THV groups.The rates of both major vascular complication and paravalvular regurgitation(PVR)>1 were almost 4 times lower in the S3-THV group than the XT-THV group(major vascular complication: 2.8% vs 9.9%,P<0.0001:PVR>1: 2.4% vs 9.7%,P<0.0001).However,the rate of new pacemaker implantation was almost twice as high in the S3-THV group(17.3% vs 9.8%,P=0.03).In the S3 group,independent predictors of new permanent pacemaker were pre-procedural RBBB(OR=4.9:P=0.001),pre-procedural PR duration(OR=1.14,P=0.05) and device lack of coaxiality(OR=1.13:P=0.05) during deployment.CONCLUSION The S3-THV is associated to lower rates of major vascular complications and PVR but higher rates of new pacemaker compared to the XT-THV.Sub-optimal visualization of the S3-THV in relation to the aortic valvular complex during deployment is a predictor of new permanent pacemaker. | Fadi J Sawaya Marco Spaziano Thierry Lefèvre Andrew Roy Phillippe Garot Thomas Hovasse Antoinette Neylon Hakim Benamer Mauro Romano Thierry Unterseeh Marie-Claude Morice Bernard Chevalier | 2016 | World Journal of Cardiology2016，8，12： | 2 |
| 5 | Cilostazol for secondary stroke prevention:systematic review and meta-analysis显示文摘Background Stroke is one of the leading causes of death worldwide.Cilostazol,an antiplatelet and phosphodiesterase 3 inhibitor,has not been clearly established for ischaemic stroke use.We aim to determine the efficacy and safety of cilostazol for secondary stroke prevention.Methods MEDLINE,EMBASE,Cochrane Library,Web of Science and ClinicalTrials.gov were searched from inception to 25 September 2020,for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo,in patients with ischaemic stroke.Version 2 of the Cochrane risk-of-bias tool for randomised trials(RoB 2)was used to assess study quality.This meta-analysis was reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)statement.Results Eighteen randomised trials comprising 11429 participants were included in this meta-analysis.Most trials possessed low risk of bias and were of low heterogeneity.Cilostazol significantly reduced the rate of ischaemic stroke recurrence(risk ratio,RR=0.69,95%CI 0.58 to 0.81),any stroke recurrence(RR=0.64,95%CI 0.54 to 0.74)and major adverse cardiovascular events(RR=0.67,95%CI 0.56 to 0.81).Cilostazol did not significantly decrease mortality(RR=0.90,95%CI 0.64 to 1.25)or increase the rate of good functional outcome(Modified Rankin Scale score of 0–1;RR=1.07,95%CI 0.95 to 1.19).Cilostazol demonstrated favourable safety profile,significantly reducing the risk of intracranial haemorrhage(RR=0.46,95%CI 0.31 to 0.68)and major haemorrhagic events(RR=0.49,95%CI 0.34 to 0.70).Conclusions Cilostazol demonstrated superior efficacy and safety profiles compared with traditional antiplatelet regimens such as aspirin and clopidogrel for secondary stroke prevention but does not appear to affect functional outcomes.Future randomised trials can be conducted outside East Asia,or compare cilostazol with a wider range of antiplatelet agents. | Choon Han Tan Andrew GR Wu Ching-Hui Sia Aloysius ST Leow Bernard PL Chan Vijay Kumar Sharma Leonard LL Yeo Benjamin YQ Tan | 2021 | Stroke & Vascular Neurology2021，6，3： | 2 |
| 6 | Exceptional exporter performance: cause, effect, or both?显示文摘 | Andrew B. Bernard J. Bradford Jensen | 1998 | Journal of International Economics1998，，1： | 2 |
| 7 | Who wins the olympic games: economic resources and medals totals显示文摘 | BERNARD ANDREW B MEGHAN R BUSSE | 2004 | Rev Eco Statistics2004，86，1： | 1 |
| 8 | Comparative Advantage and Heterogeneous Firms显示文摘 | Bernard Andrew Stephen Redding and Peter Schott | 2007 | Review of Economic Studies2007，73，1： | 1 |
| 9 | Serum Albumin Level as a Predictor of Outcome in Traumatic Brain Injury: Potential for Treatment显示文摘 | Francis Bernard Yahia Z. Al-Tamimi Doris Chatfield Andrew G. Lynch Basil F. Matta David K. Menon | 2008 | The Journal of Trauma: Injury, Infection, and Critical Care2008，，4： | 1 |
| 10 | Export entry and exit by German firms显示文摘 | Andrew B. Bernard Joachim Wagner | | Weltwirtschaftliches Archiv0，，： | 1 |
| 11 | Investigation of benzene oxide in bone marrow and other tissues of F344 rats following metabolism of benzene in vitro and in vivo 显示文摘 | Andrew B L Karen YO C Suramya W Thomas A M Bernard T G Stephen M R | 1998 | Chemical Research in Toxicology1998，11，4： | 1 |
| 12 | Do medical students respond empathetically to a virtual patient?显示文摘 | Adeline M. Deladisma Marc Cohen Amy Stevens Peggy Wagner Benjamin Lok Thomas Bernard Christopher Oxendine Lori Schumacher Kyle Johnsen Robert Dickerson Andrew Raij Rebecca Wells Margaret Duerson J. Garrett Harper D. Scott Lind | 2007 | The American Journal of Surgery2007，，6： | 1 |
| 13 | Feasibility study of floating windfarms in shallow offshore sites显示文摘 | Andrew R. Henderson Bernard Bulder Rene Huijsmans Johan Peeringa Jan Pierik Erik Snijders Martin van Hees Geert H. Wijnants Martijn J. Wolf | 2009 | Wind Engineering2009，，5： | 1 |
| 14 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 15 | β-Glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections显示文摘 | Cheol-Heui Yun Alberto Estrada Andrew Van Kessel Byung-Chul Park Bernard Laarveld | 2003 | FEMS Immunology and Medical Microbiology2003，，1： | 1 |
| 16 | Crystal structure of glycyl endopeptidase frome Carica papaya: a cysteine endopeptidase of unusual substrate specificity显示文摘 | Bernard P O H Andrew M H David J B | 1995 | Biochemistry1995，34，13： | 1 |
| 17 | Plants and productivity in international trade 显示文摘 | BERNARD ANDREW B JONATHAN EATON J | 2003 | American Economic Re- view2003，，93： | 1 |
| 18 | Biceps tenotomy versus tenodesis: a review of clinical outcomes and biomechanical results显示文摘 | Andrew R. Hsu Neil S. Ghodadra CDR Matthew T. Provencher Paul B. Lewis Bernard R. Bach | 2011 | Journal of Shoulder and Elbow Surgery2011，，2： | 1 |
| 19 | The S pot sign and T ranexamic acid O n P reventing ICH growth – AUS tralasia T rial ( STOP‐AUST ): Protocol of a phase II randomized, placebo‐controlled, double‐blind, multicenter trial显示文摘 | Atte Meretoja Leonid Churilov Bruce C. V. Campbell Richard I. Aviv Nawaf Yassi Christen Barras Peter Mitchell Bernard Yan Harshal Nandurkar Christopher Bladin Tissa Wijeratne Neil J. Spratt Jim Jannes Jonathan Sturm Jayantha Rupasinghe Jorge Zavala Andrew | 2014 | Int J Stroke2014，，： | 1 |
| 20 | Convergence in International Output显示文摘 | Andrew B Bernard Steven N Durlauf | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员